These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30134055)

  • 1. Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features.
    Ray Chaudhuri K; Poewe W; Brooks D
    Mov Disord; 2018 Jul; 33(6):909-919. PubMed ID: 30134055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-related motor complications--phenomenology.
    Fox SH; Lang AE
    Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease.
    Erro R; Picillo M; Amboni M; Moccia M; Vitale C; Longo K; Pellecchia MT; Santangelo G; Martinez-Martin P; Chaudhuri KR; Barone P
    Mov Disord; 2015 Mar; 30(3):373-8. PubMed ID: 25648938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical spectrum of levodopa-induced complications.
    Aquino CC; Fox SH
    Mov Disord; 2015 Jan; 30(1):80-9. PubMed ID: 25488260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of levodopa.
    Beaulieu-Boire I; Lang AE
    Mov Disord; 2015 Jan; 30(1):90-102. PubMed ID: 25491470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
    Prashanth LK; Fox S; Meissner WG
    Int Rev Neurobiol; 2011; 98():31-54. PubMed ID: 21907082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Picconi B; Hernández LF; Obeso JA; Calabresi P
    Mov Disord; 2018 Jul; 33(6):867-876. PubMed ID: 29219207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced Parkinson's disease.
    Diamond A; Jankovic J
    Expert Rev Neurother; 2006 Aug; 6(8):1181-97. PubMed ID: 16893346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa: A new look at an old friend.
    Olanow CW; Stocchi F
    Mov Disord; 2018 Jul; 33(6):859-866. PubMed ID: 29178365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J; Ibáñez R; Gudín M; Hernández A
    Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
    Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
    Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of current Parkinson's disease therapy.
    Rascol O; Payoux P; Ory F; Ferreira JJ; Brefel-Courbon C; Montastruc JL
    Ann Neurol; 2003; 53 Suppl 3():S3-12; discussion S12-5. PubMed ID: 12666094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact and management of nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.